AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
ApexOnco Front Page
Recent articles
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
The company’s TRPV1 antagonist looks doomed.
The company admits defeat with zelenectide.
But this comes in second-line breast cancer, a use the group isn’t pursuing.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Ascentage hopes to become a new force in BTK.
